about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesHormonal therapy in advanced or recurrent endometrial cancerEndometrial cancer: what is new in adjuvant and molecularly targeted therapy?Molecular profiling of endometrial malignancies.Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24.Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.Evaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer.MUC1 stimulates EGFR expression and function in endometrial cancer.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review.Reciprocal crosstalk between endometrial carcinoma and mesenchymal stem cells via transforming growth factor-β/transforming growth factor receptor and C-X-C motif chemokine ligand 12/C-X-C chemokine receptor type 4 aggravates malignant phenotypes.Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.
P2860
Q21129302-C52A227F-0B32-496D-90B4-AB8BAEE77EDBQ24235543-A98735C9-FB3A-4F70-9DFD-EE3734213943Q33633962-D5DB8D38-C7D8-4C2E-B30B-BA6EDBE16DB6Q33757898-1A5A6B27-ECCB-4360-A158-AFE0074B16BBQ34041350-1B5B69C6-D57F-4B69-A2DB-0B6B61955B4FQ34397557-760B354A-9B34-4B5C-8D12-C2853BC3CCD6Q34571141-8F7AE41F-191F-44BE-9009-E8E10AF1B411Q36577722-34DF52F1-F58E-40D1-A615-76490B889B43Q37139199-D4DD6E1B-DDCE-44D1-ABE7-07E8B3310843Q37471173-523BC4FE-FC80-4BA2-987E-5AA5C20E2BA1Q39840036-45056010-CB0C-4358-AA18-A313A91ABFC6Q45848384-F4893564-1638-4D49-AA04-D74537C69584Q48516369-FC225429-1914-46CF-B41B-5EE2BF6AA8E8Q49259696-F3A665D1-5E68-402E-9CB2-D3AFDB72FD91Q52626866-B8CDDF19-7E08-4CB3-84BF-24C508361573Q52751765-7873F696-1C35-48DF-9E36-A80C71E387AA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current treatment of metastatic endometrial cancer.
@en
Current treatment of metastatic endometrial cancer.
@nl
type
label
Current treatment of metastatic endometrial cancer.
@en
Current treatment of metastatic endometrial cancer.
@nl
prefLabel
Current treatment of metastatic endometrial cancer.
@en
Current treatment of metastatic endometrial cancer.
@nl
P2860
P1433
P1476
Current treatment of metastatic endometrial cancer.
@en
P2093
Gini Fleming
Sarah M Temkin
P2860
P356
10.1177/107327480901600106
P577
2009-01-01T00:00:00Z